CIBC Asset Management Inc Makes New $242,000 Investment in Repligen Co. (NASDAQ:RGEN)

CIBC Asset Management Inc acquired a new position in Repligen Co. (NASDAQ:RGEN) in the 3rd quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm acquired 1,625 shares of the biotechnology company’s stock, valued at approximately $242,000.

Several other hedge funds also recently made changes to their positions in RGEN. Andra AP fonden bought a new stake in Repligen during the second quarter valued at $25,000. International Assets Investment Management LLC purchased a new stake in shares of Repligen during the second quarter worth about $33,000. UMB Bank n.a. increased its stake in shares of Repligen by 138.3% during the third quarter. UMB Bank n.a. now owns 224 shares of the biotechnology company’s stock valued at $33,000 after buying an additional 130 shares during the period. Lazard Asset Management LLC increased its position in Repligen by 206.1% during the 1st quarter. Lazard Asset Management LLC now owns 202 shares of the biotechnology company’s stock valued at $36,000 after purchasing an additional 136 shares during the period. Finally, Blue Trust Inc. boosted its position in Repligen by 113.4% during the 3rd quarter. Blue Trust Inc. now owns 239 shares of the biotechnology company’s stock valued at $36,000 after acquiring an additional 127 shares in the last quarter. 97.64% of the stock is currently owned by hedge funds and other institutional investors.

Analyst Ratings Changes

RGEN has been the subject of a number of recent research reports. UBS Group lowered their price target on shares of Repligen from $205.00 to $185.00 and set a “buy” rating for the company in a research report on Wednesday, July 31st. Wells Fargo & Company began coverage on Repligen in a research report on Tuesday, August 27th. They issued an “overweight” rating and a $180.00 target price on the stock. Wolfe Research started coverage on Repligen in a research note on Thursday, November 14th. They issued a “peer perform” rating for the company. Stephens reaffirmed an “overweight” rating and set a $170.00 price target on shares of Repligen in a report on Tuesday, July 30th. Finally, Benchmark reaffirmed a “hold” rating on shares of Repligen in a research note on Monday, August 5th. Four analysts have rated the stock with a hold rating and eight have issued a buy rating to the company. Based on data from MarketBeat, Repligen has a consensus rating of “Moderate Buy” and a consensus price target of $190.25.

Insider Activity at Repligen

In related news, Director Anthony Hunt sold 22,191 shares of Repligen stock in a transaction dated Tuesday, September 10th. The stock was sold at an average price of $145.37, for a total value of $3,225,905.67. Following the completion of the sale, the director now directly owns 139,840 shares in the company, valued at $20,328,540.80. The trade was a 13.70 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available through the SEC website. 1.20% of the stock is currently owned by company insiders.

Repligen Trading Up 0.6 %

Shares of RGEN stock opened at $142.58 on Friday. The stock’s 50 day simple moving average is $140.20 and its two-hundred day simple moving average is $143.62. Repligen Co. has a 1 year low of $113.50 and a 1 year high of $211.13. The company has a market cap of $7.99 billion, a PE ratio of -385.34, a price-to-earnings-growth ratio of 3.87 and a beta of 0.96. The company has a debt-to-equity ratio of 0.26, a current ratio of 10.44 and a quick ratio of 5.56.

Repligen (NASDAQ:RGEN) last announced its quarterly earnings data on Tuesday, November 12th. The biotechnology company reported $0.43 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.34 by $0.09. The business had revenue of $154.87 million during the quarter, compared to the consensus estimate of $153.34 million. Repligen had a negative net margin of 3.36% and a positive return on equity of 3.90%. The firm’s quarterly revenue was up 9.7% compared to the same quarter last year. During the same quarter last year, the firm earned $0.23 earnings per share. Research analysts predict that Repligen Co. will post 1.52 earnings per share for the current year.

Repligen Profile

Repligen Corporation develops and commercializes bioprocessing technologies and systems for use in biological drug manufacturing process in North America, Europe, the Asia Pacific, and internationally. It offers Protein A ligands that are the binding components of Protein A affinity chromatography resins; and cell culture growth factor products.